Acquired Thrombotic Thrombocytopenic Purpura After BNT162b2 COVID-19 Vaccine: Case Report and Literature ReviewArticle Published on 2022-11-032022-11-15 Journal: Laboratory medicine [Category] 진단, [키워드] Acquired ADAMTS Anemia autoantibody Blood BNT162b2 BNT162b2 vaccine caplacizumab caused Complete COVID-19 COVID-19 vaccine deficiency Diagnosis gastrointestinal symptoms immunosuppressive literature microangiopathy MOST occurred outcome Patient patients Pfizer-BioNTech plasma positive Prednisone presenting report reported review second dose significantly the patient therapy thrombocytopenia thrombosis thrombotic Thrombotic thrombocytopenic purpura treated Treatment Vaccine vaccine. was used [DOI] 10.1093/labmed/lmac016 PMC 바로가기
Acute asthma exacerbation due to the SARS-CoV-2 vaccine (Pfizer-BioNTech BNT162b2 messenger RNA COVID-19 vaccine [ComirnatyⓇ])Article Published on 2022-11-012022-11-15 Journal: International Journal of Infectious Diseases [Category] SARS, 진단, [키워드] acute exacerbation Adverse Adverse reaction Asthma BNT162b2 center Control COVID-19 vaccine dose effective eligible eosinophilia eosinophils Hospitalization individuals life-threatening Messenger RNA Patient Pfizer-BioNTech prevention receiving repeated risk factor SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccine, Acute asthma exacerbation sensitization Sensitization. the patient the SARS-CoV-2 vaccination Vaccine [DOI] 10.1016/j.ijid.2022.09.019 PMC 바로가기
Development of IgA vasculitis with severe glomerulonephritis after COVID-19 vaccination: a case report and literature reviewArticle Published on 2022-11-012022-11-15 Journal: CEN case reports [Category] 진단, [키워드] accompanied Acute kidney injury administration applied Case report COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine Cyclophosphamide development Glomerulonephritis Hematuria IgA IgA Vasculitis IgAV. Immunosuppressive treatment initial injection Intensive intractable intravenous Japanese kidney literature review nephropathy oral steroid Patient performed Pfizer-BioNTech pulse purpura remained renal function reported resolved second dose second vaccination Spread syndrome Treatment Vasculitis [DOI] 10.1007/s13730-022-00695-1 PMC 바로가기
BNT162b2 against COVID-19 in Brazil using a test-negative design: Study protocol and statistical analysis planArticle Published on 2022-10-202022-11-16 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory symptom approved BNT162b2 Brazil Care case-control study collected conducted Control COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19-related complication Effectiveness Enrollment Ethics evaluate Evidence Follow-up identify material Mutation Older Patient peer-reviewed performed Pfizer-BioNTech polymerase chain populations positive protocol public health randomized clinical trials Research Ethics Committee reverse transcription RT-PCR SARS-CoV-2 SARS-CoV-2 variants screened seeking Statistical analysis plan Study protocol symptomatic tested vaccination [DOI] 10.1371/journal.pone.0276384 PMC 바로가기
Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infectionArticle Published on 2022-10-172022-11-15 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 진단, [키워드] assays BNT162b2 BNT162b2 vaccine class correlated demonstrated develop dose doses epitope exhibited Frequency greater healthcare worker healthy IFN-γ IgG response IL-2 IL2 Immunity individual infected with SARS-CoV-2 Infection Interferon-gamma interleukin-2 magnitude Moderna mRNA-1273 vaccine mononuclear cell mRNA-1273 N and M nine participant Participants PCR testing peptide Peripheral blood Pfizer-BioNTech positive Post-infection Proteins proteome repeated responders response responses against robust S glycoprotein S1 and S2 S2 subunit SARS-CoV-2 SARS-COV-2 infection structural protein subunit subunits T cell response T-cell Response the SARS-CoV-2 uninfected vaccination vaccinee was determined were expressed with COVID-19 [DOI] 10.1371/journal.pone.0276241 PMC 바로가기
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and WalesArticle Published on 2022-10-152022-11-16 Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI adjusted age analyses analysis Analysis aRR association B.1.1.529 benefit BNT162b2 booster booster dose Booster vaccine calculated ChAdOx1 nCoV-19 Chronic kidney disease Committee Comorbidities Comorbidity conducted core covariates COVID-19 COVID-19 hospitalisation COVID-19 infection COVID-19 therapeutics COVID-19 vaccination current death dominant Edinburgh England event group Health health condition high risk hospitalisation identify immunisation Immunosuppressant increased risk individual initial Innovation Ireland male Medical Research Council meta-analyses Moderna mortality data mRNA-1273 Multimorbidity National of BNT162b2 offer older adult outcome outcomes Oxford-AstraZeneca per 1000 person-year per 1000 person-years Pfizer-BioNTech Poisson regression model primary care prospective cohort prospective cohort study rate ratio receiving reduced reduced risk remained risk risk factor RT-PCR testing SARS-COV-2 infection Scottish severe COVID-19 Sex those with comorbidity university vaccination Vaccine vaccine dose vaccine group variant [DOI] 10.1016/S0140-6736(22)01656-7 PMC 바로가기
Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics studyArticle Published on 2022-10-142022-11-15 Journal: eLife [Category] COVID19(2023년), SARS, 바이오마커, 진단, [키워드] Abuse Accelerator Antibody Response association Biomarker BNT162b2 characterized clinical trial coronavirus Course COVID-19 COVID-19 patients Critical CXCL10 cytokine dataset develop Disease progression Donor drug early IFN signaling Eiger BioPharmaceuticals enrolled Enrollment heterogeneity Host identify immune immune marker immune response immune signature immunological immunology independent individual Infection Infectious disease Inflammation machine-learning majority marker MCP-3 MCP1 Medicine memory Mild mRNA vaccination natural infection outcome Outpatient outpatients Patient Pfizer-BioNTech plasma plasma protein Post-infection predict Predictive Predictive modeling proteomics provided receiving RIG-I SARS-CoV-2 SARS-CoV-2-infected patients severe symptoms Stanford Stanford University subsequent systems immunology T cell T cell memory the antibody response trajectory transcriptomics Vaccine viral shedding Virological viruses viruses. with COVID-19 [DOI] 10.7554/eLife.77943 PMC 바로가기
Comparative Analysis of Antibody Titers against the Spike Protein of SARS-CoV-2 Variants in Infected Patient Cohorts and Diverse Vaccination RegimesArticle Published on 2022-10-132022-11-15 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] accompanied antibody Antibody Response AstraZeneca B cell benefit booster vaccination cells Comparative courses COVID-19 COVID-19 pandemic Critical critical COVID-19 patients exceeded follicular Frequency Infection Inflammation Inflammatory response Johnson & Johnson long-COVID Lymphocytes Mild Moderna mRNA vaccine neutralizing antibody patients patients who survived Pfizer-BioNTech recommendation reduced regime SARS-CoV-2 SARS-CoV-2 patient severe COVID-19 disease the SARS-CoV-2 virus the Spike titer understanding vaccination Vaccination strategy vaccination. Vaccine [DOI] 10.3390/ijms232012231 PMC 바로가기
Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Residents of US Nursing Homes Before and During the Delta Variant Predominance, December 2020-November 2021Article Published on 2022-10-032022-11-16 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome adjusted Against coronavirus coronavirus 2 coronavirus disease Coverage COVID-19 COVID-19 vaccine Cox proportional hazard Critical Delta dose effective Effectiveness evaluated hazard ratio home Infection maintaining Moderna morbidity and mortality Nursing nursing home residents Pfizer-BioNTech preventing infection provided Rate resident respiratory retrospective cohort SARS-CoV-2 SARS-COV-2 infection second dose vaccination Vaccine vaccine effectiveness. was used [DOI] 10.1093/cid/ciac562 PMC 바로가기
Seizures following COVID-19 vaccination in Mexico: A nationwide observational studyArticle Published on 2022-10-012022-11-16 Journal: Epilepsia [Category] COVID19(2023년), SARS, 치료기술, [키워드] Administered administration adverse events approval BNT162b2 conducted COVID-19 COVID-19 pandemic COVID-19 vaccination detect dose effective vaccine epidemiological epilepsy events first dose highest incidence incidence rate Moderna mRNA-1273 Patient patients Pfizer-BioNTech recipient retrospective SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines Seizure Seizures seizures. Surveillance trials Vaccine [DOI] 10.1111/epi.17390 PMC 바로가기